Clinical Trial Update: First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

First-in-man dose-escalation Phase 1 trial evaluating the MET kinase inhibitor MSC2156119J in patients with advanced solid tumors, completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumor

Drugs mentioned

• MSC2156119J (MSC2156119J)

Snippet

Sponsor: EMD Serono | Conditions: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available | Phase 1 | Status: COMPLETED | Results posted: 2017-04-17